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Abstract 24 
The aim of this study was to microencapsulate Bifidobacterium longum subsp. infantis CCUG 25 
52486 using the extrusion method in a variety of matrices, namely sodium alginate (SA), 26 
sodium alginate-cow milk (SACM), sodium alginate-goat milk (SAGM) and sodium alginate-27 
casein hydrolysate (SACH), and to evaluate the survival of free and encapsulated bacterial cells 28 
under different conditions. The encapsulation yield, size and surface morphology of the 29 
microcapsules were evaluated. The survival of microencapsulated bacterial cells and free 30 
bacterial cells were evaluated under simulated gastrointestinal conditions as well as in 31 
refrigeration, cow milk and goat milk during storage at 4 oC for 28 days. The average size of 32 
SACM capsules and SAGM capsules was 2.8±0.3 mm and 3.1±0.2 mm respectively.  Goat 33 
milk and cow milk based matrices resulted in dense microcapsules which led to better 34 
performances in simulated gastrointestinal conditions than SA and SACH microcapsules. The 35 
bacterial cells encapsulated in SAGM showed the highest survival rate in cow milk (7.61 log 36 
cfu g-1) and goat milk (8.10 log cfu g-1) after the storage of 28 d. The cells encapsulated in SA 37 
and SACH and the free cells performed poorly under the simulated gastrointestinal conditions 38 
and in all different storage conditions. This study showed that SACM and SAGM are suitable 39 
to encapsulate B. longum subsp. infantis CCUG 52486 using the extrusion technique and more 40 
specifically, SAGM has a potential to be used as a new encapsulation material for 41 
encapsulating probiotic bacteria, resulting milk and goat milk-based products with higher 42 
probiotic cell concentrations during refrigerated storage. 43 
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1. Introduction 47 
Bifidobacteria are a major group of probiotic microorganisms, which have been widely 48 
researched for their probiotic properties. Bifidobacteria are considered to exert many beneficial 49 
effects to the human host such as alleviation of lactose intolerance, reduction of serum 50 
cholesterol levels, synthesis of some vitamins, prevention of colonization of pathogens, 51 
modulation of the immune system, reduction of symptoms of irritable bowel disease, and 52 
prevention of diarrhoea (Shah, 2007; Xiao et al., 2003). They have been shown to be suitable 53 
for incorporation as a co-starter in different food products including dairy-based food 54 
formulations (Bunesova et al., 2015; Prasanna et al., 2014). The therapeutic concentration of 55 
probiotic bacteria in a product should be around 6 log CFU g−1 until the end of their shelf life 56 
(Donkor et al., 2006). In addition, bifidobacteria must endure the high acidic condition in the 57 
stomach and hydrolytic enzymes and bile salts in the small intestine prior to reaching the colon 58 
in large quantities, which is essential for effective permanent or transient colonization of 59 
bacteria (Song et al., 2013). Furthermore, most strains of bifidobacteria show poor growth and 60 
viability in milk and fermented milk products (Ranadheera et al., 2014). 61 
 62 
In this context, microencapsulation has been widely researched to create a physical barrier 63 
protecting the bacteria from adverse conditions during production processes and digestion 64 
(Fritzen-Freire et al., 2012). There are many microencapsulation techniques which have been 65 
used with probiotics such as emulsion, extrusion, spray drying, freeze drying, coacervation, 66 
fluidized bed coating and phase separation (Rajam et al., 2012). Most of these techniques 67 
involve harsh processing conditions, which directly affect the viability and the performances 68 
of the encapsulated probiotic bacteria. However, the extrusion method involves mild conditions 69 
during probiotic encapsulation (Shi et al., 2013a). In this method, a hydrocolloid solution 70 
containing concentrated probiotic bacteria is dropped into a solidifying solution. Sodium 71 
alginate obtained from brown seaweed has been widely researched as an encapsulation material 72 
for probiotics. However, alginate cannot protect effectively probiotic bacteria from the highly 73 
acidic environment due to the porous structure of alginate beads, which supports the easy 74 
diffusion of acid and other materials inside (Rajam et al., 2012). Therefore, it is recommended 75 
to blend or coat alginate with other filler materials to overcome the above-mentioned 76 
disadvantages (Cook et al., 2013). 77 
 78 
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Many studies have reported the effectiveness of different alginate based matrices for 79 
microencapsulation of probiotic, such as alginate-starch (Sultana et al., 2000), alginate-80 
chitosan (Chávarri et al., 2010; Krasaekoopt et al., 2004), alginate-gelatin (Li et al., 2009), 81 
alginate-pectin (Sandoval-Castilla et al., 2010) and alginate-whey protein (Gbassi et al., 2009). 82 
In addition, there has been a considerable interest in using dairy-based matrices to encapsulate 83 
probiotic bacteria, since these materials contain lactose and proteins which can provide good 84 
protection for cells during the handling and digestion process (Maciel et al., 2014). Milk and 85 
milk proteins are used in many food formulations and are widely accepted by consumers due 86 
to unique physicochemical properties. In the context of encapsulation, milk and milk proteins 87 
have technological properties such as high buffering capacity, good emulsification properties 88 
and the ability to make networks, even at low concentration (Würth et al., 2015). In addition, 89 
it is reported that microcapsules containing dairy proteins can lead to higher bacterial survival 90 
during digestion (Burgain et al., 2014). Furthermore, usage of milk based materials for 91 
encapsulation of microorganisms would be suitable to be used in dairy-based food products 92 
with improved physicochemical properties (Ranadheera et al., 2016). Therefore, there is a high 93 
potential to use different milk types and milk based proteins with alginate to encapsulate, 94 
protect and control the release of probiotic bacteria in the digestive tract (Özer et al., 2009; 95 
Ranadheera et al., 2015).   96 
However, there are few recorded reports on the effect of different alginate-dairy based matrices 97 
on encapsulation of bifidobacteria. In addition, to the best of authors’ knowledge goat milk has 98 
not been used with alginate to encapsulate bifidobacteria using the extrusion technique. 99 
Therefore, the aim of this study was to evaluate the survival of Bifidobacterium longum subsp. 100 
infantis CCUG 52486 encapsulated in sodium alginate, sodium alginate-cow milk, sodium 101 
alginate-goat milk and sodium alginate-casein hydrolysate in simulated gastrointestinal 102 
conditions and during storage in cow milk, goat milk and refrigeration at 4 oC for 28 days. This 103 
Bifidobacterium strain was selected as in our previous studies, it was shown to produce an 104 
exopolysaccharide (EPS) in milk (Prasanna et al., 2012) and to improve the physicochemical 105 
and rheological properties of low-fat set yoghurt (Prasanna et al., 2013). In addition, this strain 106 
has been characterized as a probiotic strain (Gougoulias et al., 2008) and to have a high a high 107 
angiotensin-I-converting enzyme (ACE) inhibitory activity in fermented milk (Gonzalez-108 
Gonzalez et al., 2011)  109 
 110 
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2. Materials and methods 111 
 Bacterial strain and growth conditions 112 
B. longum subsp. infantis CCUG 52486 was obtained from the culture collection of the 113 
University of Göteborg in Sweden. The cell bank of microorganism was stored at −80 °C in 114 
Wilkins-Chalgren (WC) anaerobe broth (Oxoid, Hampshire, UK) containing 15% (v/v) 115 
glycerol. The frozen stock was initially propagated in Bifidobacteria Selective Medium (BSM) 116 
agar (Sigma-Aldrich, Dorset, UK) under anaerobic conditions at 37 °C for 72 h. Two 117 
successive cultures of bacteria were carried out in WC broth (Oxoid, UK) under anaerobic 118 
condition at 37 °C for 18 h. Subsequently, a cell aliquot of the preculture (1%, v/v) was used 119 
to inoculate 200 mL of WC broth (Oxoid, UK) and incubated at 37 °C for 18 h under anaerobic 120 
condition. Bacterial cells were harvested after by centrifugation at 10,000 rpm for 10 min at 4 121 
°C. The pellet was washed with sterile phosphate buffered saline (PBS) (Oxoid, UK) and 122 
aseptically resuspended in 10 mL of PBS (Oxoid, UK) to prepare the concentrated cell 123 
suspension. 124 
 125 
 Encapsulation of B. longum subsp. infantis CCUG 52486 126 
Sterilized cow milk and sterilized goat milk were purchased from a local supermarket. Casein 127 
hydrolysate solution (2%, w/v, Sigma-Aldrich, UK) and sodium alginate solution (2%, w/v, 128 
low viscosity, Sigma-Aldrich, UK) were sterilized at 121 oC for 15 min. Three different 129 
alginate-dairy based microsphere formulations were prepared. They were SACM (sodium 130 
alginate/cow milk = 1.5/1, v/v), SAGM (sodium alginate/goat milk = 1.5/1, v/v) and SACH 131 
(sodium alginate/casein hydrolysate = 1.5/1, v/v); SA (sodium alginate) was used as the 132 
control. Each alginate-based formulation was mixed with the concentrated cell suspension at a 133 
ratio of 4:1 (alginate-based mixture solution: the concentrated cell suspension, v/v). In the case 134 
of free cells, 10 mL of the concentrated cell suspension was mixed with 40 mL of PBS (Oxoid, 135 
UK). The hydrocolloid-cell suspensions were dropped through a 21G needle into sterile 0.1 M 136 
CaCl2 (Sigma-Aldrich, UK) under gentle stirring; the dropping height was 10 cm. 137 
Microcapsules were allowed to harden for 30 minutes and were then washed with sterile PBS 138 
(Oxoid, UK) and stored in sterilized plastic containers at 4 oC. The cell concentration 139 
encapsulated in the microcapsules was around 9 log cfu g-1. 140 
 141 
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 Determination of encapsulation yield and size of alginate–milk microcapsules 142 
The encapsulation yield (EY) was determined using the following equation. EY = (Number of 143 
cells released from microcapsules) / (Number of cells added to the respective alginate based 144 
microsphere formulation) X 100. The size of different microcapsules was measured using a 145 
vernier caliper. For this, 30 microcapsules were randomly selected from each microsphere 146 
formulation to calculate the mean size. 147 
 148 
 Determination of viability of free and encapsulated bacteria 149 
Samples of free B. longum subsp. infantis cells were serially diluted in PBS (Oxoid, UK) and 150 
100 µL aliquots were plated on BSM agar (Sigma-Aldrich, UK) to enumerate the viable 151 
bacterial counts. The plates were incubated under anaerobic conditions at 37 °C for 72 h. In 152 
the case of encapsulated bacteria, the samples were completely dissolved in sterilized 50 mM 153 
sodium citrate (Sigma-Aldrich, UK) solution at pH 7.5 before plating as described by Shi et al. 154 
(2013a). For this, 1 g of the encapsulated bacteria was dissolved in 9 mL sodium citrate and 155 
the samples were serially diluted in PBS (Oxoid, UK). Aliquots of 100 µL of the serially diluted 156 
sample were plated on BSM agar (Sigma-Aldrich, UK) and after incubation, the viable cell 157 
counts were enumerated. 158 
 159 
 Survival of free and encapsulated bacteria in simulated gastrointestinal conditions 160 
Simulated gastric juice (SGJ) was prepared by dissolving 0.2% NaCl (w/v) in 0.08 M HCl, at 161 
pH 2 as described by Sun and Griffiths (2000). The microcapsules (1 g) or the free cells (1 mL) 162 
were added to glass tubes containing 9 mL of sterilized SGJ and placed in a water bath at 37 163 
oC. Samples were taken at 0, 30, 60 and 120 min, during incubation. For the free cells, the 164 
samples were taken and centrifuged at 10,000 rpm for 10 min, at 4 °C. The pellet was dissolved 165 
in PBS (Oxoid, UK) and used for cell enumeration. In the case of microencapsulated bacterial 166 
cells, the microcapsules were separated from the samples and dissolved in sodium citrate (50 167 
mM) before plating. For enumeration, all samples were serially diluted in PBS (Oxoid, UK) 168 
and viable cells were enumerated as described in Section 2.4. 169 
 170 
Simulated intestinal juice (SIJ) was prepared as described by Chávarri et al. (2010). For this, 3 171 
g of bile salt (Sigma-Aldrich, UK) were dissolved in 1 L of intestinal model solution (6.5 g/L 172 
 7 
NaCl, 0.835 g/L KCl, 0.22 g/L CaCl2 and 1.386 g/L NaHCO3), at pH 7.5. Microcapsules (1 g) 173 
or the free cells (1 mL) were added to glass tubes containing 9 mL of sterilized SIJ and placed 174 
in a water bath at 37 oC. The sampling and enumeration of free and encapsulated B. longum 175 
subsp. infantis CCUG 52486 were carried out as described previously.  176 
 177 
 Survival of free and microencapsulated bacterial cells in refrigeration, cow milk and goat 178 
milk during refrigerated storage 179 
In the case of refrigerated storage, microcapsules or free cells were stored (1 g for 180 
microcapsules/ 1 mL for free cells in each portion) in sterilized centrifuge tubes (15 mL 181 
capacity, polypropylene, Fisher Scientific, Loughborough, UK), at 4 oC for 28 days. In the case 182 
of cow milk, 1 mL of the free cells or 1 g of the encapsulated bacteria was mixed with 10 mL 183 
of sterilized cow milk in sterilized centrifuge tubes (15 mL capacity, polypropylene, Fisher 184 
Scientific, UK). In the case of goat milk, 10 mL of sterilized goat milk in sterilized centrifuge 185 
tubes (15 mL capacity, polypropylene, Fisher Scientific, UK) were mixed with 1 mL of the 186 
free cells or 1 g of the encapsulated cells. The centrifuge tubes containing free and encapsulated 187 
bacteria and inoculated milk samples were stored at 4 oC for 28 days. Afterwards, the samples 188 
were collected on 0, 7, 14, 21 and 28 days and analyzed for the viability of cells as described 189 
in Section 2.4. 190 
 191 
 Scanning electron microscopic (SEM) analysis of surface of microcapsules 192 
The microcapsules were dehydrated sequentially in a series of ethanol solutions (30, 50, 70, 193 
80, 90, and 100%). For this, the microcapsules were soaked for 15 minutes in each solution. 194 
The dehydrated microcapsules were critical point dried using a critical point dryer (Balzers 195 
CPD 030, Liechtenstein, Germany) with liquid carbon dioxide. The dried samples were fixed 196 
to the SEM stubs with double-sided tape. Afterward, the microcapsules were gold coated using 197 
an Edwards S150B sputter-coater for 2.5 min (Edwards, West Sussex, UK). The surface of 198 
coated microcapsules was examined using a scanning electron microscope (FEI, Quanta 600 199 
F, USA).  200 
 201 
 Statistical analysis 202 
All the experiments were conducted in triplicate. Results of the size of microcapsules and 203 
encapsulation efficiency were analyzed using one-way analysis of variance (ANOVA) with 204 
 8 
Turkey’s multiple comparison tests (SAS, version 9.2, SAS Institute Inc., Cary NC, USA). 205 
Results of viable counts from simulated gastrointestinal conditions and from storage studies 206 
were analyzed as a split-plot in time design using the General Linear Model (GLM) procedure 207 
of SAS, version 9.2 (SAS Institute Inc., Cary NC, USA). 208 
 209 
3. Results and discussion 210 
 Size, encapsulation yield and surface morphology of microcapsules 211 
  212 
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Table 1 shows the size of the different microcapsules. The type of encapsulation material had 213 
a significant influence (p<0.05) on the size of microcapsules. The largest microcapsules  were 214 
observed with SAGM while their sizes were not significantly different (p>0.05) with those of 215 
SACM microcapsules. The smallest microcapsules in this study were observed with SA 216 
though, the value was not significantly different with that of SACH. There is no published 217 
literature to compare with the size of SAGM microcapsules, which have been prepared using 218 
the extrusion technique. Our results showed that the addition of goat milk and cow milk to 219 
sodium alginate resulted larger microcapsules than SA and SACH. This may be due to the 220 
higher protein content of cow milk and goat milk which, can lead to higher total protein content 221 
of SACM and SAGM. Similarly, Klemmer et al. (2011) and Shi et al. (2013a) reported that the 222 
higher protein content in matrices could lead to larger microcapsules.  223 
 224 
The type of encapsulating matrices had no significant (p>0.05) effect on the encapsulation 225 
yield (  226 
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Table 1) and the values ranged from 94.1% to 95.6%. Our results are in accordance with 227 
findings of Pan et al. (2013) who reported around 99% of the encapsulation efficiency of 228 
bacteria with alginate-skim milk. The results clearly showed that there was a very low loss of 229 
cell viability during the encapsulation which was due to the mild conditions used. In general, 230 
extrusion method is commonly used with hydrocolloids and reported to yield higher 231 
encapsulation yield (Krasaekoopt et al., 2003). 232 
 233 
The surface morphology of the microcapsules was investigated using SEM micrographs. Fig.1 234 
shows the surface of different microcapsules at a magnification of 10000. Porous 235 
microcapsules were observed with SA [Fig.1 (A)]. Furthermore, SA microcapsules had cracks 236 
on their surface and could not protect entrapped cells from adverse environmental conditions. 237 
Similarly, Li et al. (2009) reported porous structure for microcapsules produced using alginate. 238 
Modification of alginate with cow milk and goat milk resulted in the microcapsules (SACM, 239 
SAGM) with denser surface morphology [Fig.1 (B) and (C)]. In addition, these microcapsules 240 
did not have cracks that could ensure high protection for encapsulated cells from adverse 241 
conditions. SACH microcapsules showed irregular surface morphology [Fig.1 (D)] which 242 
could not give better protection for entrapped cells than that of SACM and SAGM 243 
microcapsules. 244 
 245 
 Survival of free and encapsulated B. longum subsp. infantis CCUG 52486 in simulated 246 
gastric juice 247 
Microencapsulation provided a significant protection for the cells in simulated gastric juice 248 
(Fig. 2). The viable cell count of free B. longum subsp. infantis CCUG decreased significantly 249 
(p<0.05) within 90 min of the incubation period and the cell count of free cells dropped to an 250 
undetectable level (< 101 cfu mL-1) after 120 min. This is because bifidobacteria are fastidious 251 
organisms which are sensitive to acidic environment leading to challenges in industrial 252 
applications. Similarly, Lee and Heo (2000) observed a rapid reduction of the cell viability of 253 
free B. longum KCTC 3128 within 30 min when exposed to a simulated gastric environment. 254 
The present study also demonstrated that sodium alginate itself could not protect B. longum 255 
subsp. infantis CCUG from the highly acidic environment for a long time. Alginate is a 256 
copolymer and composed of D-mannuronic and L-guluronic acids. This copolymer is not stable 257 
at low pH condition (Liserre et al., 2007). Dissolution and erosion of alginate occur at low pH 258 
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and lead for destruction of capsule structure. Our results are in accordance with findings of 259 
Krasaekoopt et al. (2004) and  who reported poor viability of bacterial cells microencapsulated 260 
with alginate in simulated gastric juice. The results clearly showed that microencapsulation 261 
with SACM and SAGM gave a better protection for the cells than SA and SACH. The viable 262 
cell counts of SACM and SAGM microcapsules were 6.37 log cfu g-1 and 5.19 log cfu g-1 263 
respectively, after 120 min. The better protection observed in microencapsulated bacterial cells 264 
by cow milk and goat milk based matrices may be due to the high buffering capacity of milk 265 
proteins. In addition, milk proteins can interact with alginate and act as filling materials which 266 
can seal the porous structure of alginate-milk based microcapsules (Kailasapathy, 2006). Our 267 
results are in accordance with observations made in some other studies. Guérin et al. (2003) 268 
reported that the encapsulated bifidobacteria in a mixed gel made of alginate, pectin and whey 269 
proteins could survive better in simulated gastric juice at pH 2.5 due to buffering activities of 270 
whey proteins.  271 
 272 
 Survival of free and encapsulated bacterial cells in simulated intestinal juice 273 
The survival of free and encapsulated B. longum subsp. infantis CCUG 52486 in simulated 274 
intestinal juice at 37 oC for 2 h is presented in Fig. 3. Encapsulation gave a significant (p<0.05) 275 
protection for bacterial cells in simulated intestinal juice. The viable count of free cells showed 276 
a significant (p<0.05) decrease within 120 min. This may be due to the interaction of bile salt 277 
with the free cells leading to lose of cell wall integrity. The loss of cell wall integrity may lead 278 
to leakage of intercellular materials from the cells leading for death of cells (Bron et al., 2004). 279 
Similarly, Clark and Martin (1994) reported a rapid decrease of the viability of free cells of B. 280 
adolescentis in 2% bile salt solution at 37 oC.  281 
 282 
Milk based microcapsules (SACM and SAGM) were the most effective in protecting the cells 283 
in simulated intestinal juice. It is due to milk ingredients, which can modify the textural 284 
properties of alginate-milk based matrices [Fig.1 (B) and (C)], as the modified matrices resist 285 
the diffusion of bile salt into the microcapsules. Similarly, alginate-milk based matrices were 286 
shown to be effective in protection of Lactobacillus bulgaricus (Shi et al., 2013a; Shi et al., 287 
2013b) and Enterococcus faecalis (Shi et al., 2016) in simulated intestinal solution. SA and 288 
SACH microcapsules provided a limited protection for bacterial cells during the incubation 289 
period. This is due to the poor structure of those matrices [Fig.1 (A) and (D)], which can allow 290 
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diffusion of bile salt into the microcapsules (Hansen et al., 2002; Lee and Heo, 2000). 291 
Similarly, Krasaekoopt et al. (2004) reported poor viability of B. bifidum ATCC 1994 292 
capsulated in alginate matrices when exposed to bile salt solution. 293 
 294 
 Stability of free and encapsulated bacteria cells under refrigerated condition 295 
Fig. 4 shows the viability of free and encapsulated B. longum subsp. infantis CCUG 52486 296 
with different alginate-based matrices during the refrigerated storage at 4 oC. The cell 297 
concentration of free B. longum subsp. infantis CCUG 52486 decreased significantly (p<0.05) 298 
from 8.96 log cfu g-1 to 3.62 log cfu g-1, indicating the inability of the free cells to maintain 299 
their viability under the refrigerated storage condition. The results further revealed that 300 
encapsulation could improve the viability of bacterial cells during refrigerated storage for 28 301 
days. SA and SACH microcapsules showed higher cell viability than that of the free cells 302 
during the refrigerated storage. However, they were unable to maintain the viability of cells 303 
during the storage above the recommended count of 6 log cfu g-1. Similarly, some studies 304 
reported that encapsulation of probiotic bacteria in sodium alginate could improve the storage 305 
stability of bacterial cells than that of the free cells (Chávarri et al., 2010; Krasaekoopt et al., 306 
2004).  307 
 308 
SACM and SAGM microcapsules gave better protection for the cells during the refrigerated 309 
storage and both materials were able to maintain the cell concentrations above 6 log cfu g-1 310 
after 28 days of storage than SA and SACH. However, the final cell counts of these two 311 
microcapsules were not significantly different (p<0.05). This may be due to the denser surface 312 
morphology of alginate-dairy microcapsules [Fig.1 (B) and (C)], which can protect the 313 
encapsulated cells from adverse conditions of the environment. Similarly, some other alginate-314 
based microcapsules have been shown to be effective to give better protection for probiotics 315 
during the refrigerated storage. Encapsulation of Lactobacillus gasseri and B. bifidum in 316 
chitosan-coated alginate microspheres was shown to be effective to maintain viability 317 
throughout the storage period at 4 oC for 28 days (Chávarri et al., 2010). In addition, Zou et al. 318 
(2011) showed that chitosan-coated alginate microspheres provided a better protection for the 319 
microencapsulated B. bifidum F-35 cells than that of the free cells during the storage at 4 oC 320 
for 1 month.  321 
 322 
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 Survival of free and encapsulated bacterial cells in cow milk and goat milk at 4 oC 323 
Table 2 shows the survival of free and encapsulated stored in cow milk at 4 oC for 28 days. 324 
The results indicated that encapsulation improved the survival of bacterial cells in cow milk 325 
during storage. The free cells showed poor storage stability in cow milk where the cell 326 
concentration was significantly (p<0.05) reduced from 8.65 log cfu mL-1 to 4.38 log cfu mL-1 327 
within 28 days. SAGM microcapsules gave the best protection for the cells followed by SACM 328 
microcapsules. However, SA and SACH microcapsules could give a limited protection during 329 
the storage in cow milk. Fig. 5 shows the results of free and encapsulated bacterial counts in 330 
goat milk during storage at 4 oC for 28 days. There was a significant reduction (p<0.05) in the 331 
viability of free cells during the storage. However, the results revealed that encapsulation of B. 332 
longum subsp. infantis CCUG 52486 improved the survival of bacterial cells in goat milk 333 
during the storage period of 28 days. The highest survival of bacterial cells during the storage 334 
was observed with SAGM microcapsules followed by SACM microcapsules; where they 335 
maintained the viability of bacterial cells above 6 log cfu g-1 in goat milk during the storage 336 
period. Viable cell counts of SA and SACH microcapsules rapidly declined with the storage. 337 
 338 
Poor viability of free cells in cow milk and goat milk is due to lack of availability of small 339 
peptides and free amino acids for their growth (Gomes et al., 1998; Martı́n-Diana et al., 2003). 340 
In this study, pure goat milk and cow milk were used to inoculate bacteria without any 341 
supplementation. Similarly, Hansen et al. (2002) observed poor viability of free B. longum Bb-342 
46 cells in milk during storage at 4 oC for 16 days than that of encapsulated bacterial cells. The 343 
poor survival of bacterial cells encapsulated in SA and SACH is due to the fragile texture of 344 
walls of these microcapsules [Fig.1 (A) and (D)], which exposes bacterial cells to the external 345 
environment. The high survival rate observed with microencapsulated bacterial cells with 346 
SACM and SAGM [Fig.1 (B) and (C)] in cow milk and goat milk may be due to improved 347 
denser surface characteristics compared to SA and SACH. The modified structure of SACM 348 
and SASM could protect their content form the adverse external environments. There is no 349 
recognized published literature about the survival of bifidobacteria encapsulated using 350 
alginate-milk based matrices in goat milk during storage to compare with our results. However, 351 
some authors have reported that encapsulation can improve the viability of bifidobacteria in 352 
cow milk and cow milk-based products. Hansen et al. (2002) showed the effectiveness of 353 
alginate microcapsules to improve the viability of B. longum Bb-46 in cow milk during the 354 
storage at 4 oC for 16 days. In another study, B. bifidum encapsulated in alginate beads coated 355 
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with chitosan was shown to have better survival than the free cell in yoghurt after the storage 356 
at 4 oC for 4 weeks (Krasaekoopt et al., 2006). In addition Kailasapathy (2006) showed that the 357 
alginate-starch encapsulated B. lactis had higher survival than the free cells in yoghurt at 4 oC 358 
for 7 weeks. 359 
 360 
The present study demonstrates that encapsulation of B. longum subsp. infantis CCUG 52486 361 
in SACM and SAGM microcapsules beneficially influences the viability of bacterial cells in 362 
cow milk and goat milk during the storage at 4 oC for 28 days. Therefore, microencapsulation 363 
of bifidobacteria with SACM and SAGM could be used to enhance the growth of them in non-364 
fermented cow milk and goat milk based products. Further studies should be carried out to 365 
evaluate the effect of encapsulation of bifidobacteria with SACM and SAGM microcapsules 366 
in fermented milk-based products and other food systems. 367 
 368 
4. Conclusions 369 
The mixing of alginate with cow milk and goat milk resulted in microcapsules with denser 370 
surface and the cells encapsulated in these matrices performed better in simulated 371 
gastrointestinal conditions than the bacterial cells encapsulated in SA and SACH 372 
microcapsules. Improved structural characteristics of SACM and SAGM microcapsules could 373 
improve survival of encapsulated bacterial cells in cow milk, goat milk and refrigeration at 4 374 
oC for 28 days compared to SA and SACH microcapsules. Overall, this study showed that 375 
mixing of goat milk and cow milk with alginate improved the protection provided by modified 376 
microcapsules and could be used to improve survival of probiotic bacteria in non-fermented 377 
cow milk and goat milk based products.  378 
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Figure captions  540 
 541 
Fig.1. Scanning electron micrographs showing the surface morphology of different 542 
microcapsules. (A) SA, (B) SACM, (C) SAGM, (D) SACH (magnification 10000X). For 543 
legend explanations see Table1. 544 
 545 
Fig. 2. Survival of free and encapsulated B. longum subsp. infantis CCUG 52486 in simulated 546 
gastric juice (pH 2) at 37 oC for 120 min. Vertical lines represent standard deviations. 547 
ABCDEMeans with different uppercase are significantly different (p<0.05) between each time, 548 
for each type of alginate-dairy based microcapsule during the period of the analysis. abcdeMeans 549 
with different lowercase are significantly different (p<0.05) between each type of alginate-550 
dairy based microcapsule, for a particular time of the analysis. For legend explanations see 551 
Table1. 552 
 553 
Fig. 3. Stability of free and encapsulated B. longum subsp. infantis CCUG 52486 in simulated 554 
intestinal juice (pH 7.5) at 37 oC for 120 min. Vertical lines represent standard deviations. 555 
ABCDEMeans with different uppercase are significantly different (p<0.05) between each time, 556 
for each type of alginate-dairy based microcapsule during the period of the analysis. abcdeMeans 557 
with different lowercase are significantly different (p<0.05) between each type of alginate-558 
dairy based microcapsule, for a particular time of the analysis. For legend explanations see 559 
Table1. 560 
 561 
Fig. 4. Changes in the viable count of free and the encapsulated B. 562 
longum subsp. infantis CCUG 52486 during refrigerated storage (4 oC) for 28 days. Vertical 563 
lines represent standard deviations. ABCDEMeans with different uppercase are significantly 564 
different (p<0.05) between each time, for each type of alginate-dairy based microcapsule 565 
during the storage. abcdMeans with different lowercase are significantly different (p<0.05) 566 
between each type of alginate-dairy based microcapsule, for a particular day of the storage 567 
period. For legend explanations see Table1. 568 
 569 
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Fig. 5. Changes in the viable counts free and encapsulated bacteria in goat milk at 4 oC for 28 570 
days. Vertical lines represent standard deviations. ABCDEMeans with different uppercase are 571 
significantly different (p<0.05) between each time, for each type of alginate-dairy based 572 
microcapsule during the storage. abcdMeans with different lowercase are significantly different 573 
(p<0.05) between each type of alginate-dairy based microcapsule, for a particular day of the 574 
storage period. For legend explanations see Table1. 575 
 576 
 577 
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Table 1. Encapsulation yield and size of different microcapsules 586 
Type of microcapsules Size (mm) Encapsulation yield (%) 
SA 2.3 ± 0.4b 95.6 ± 2.1a 
SACM 2.8 ± 0.3a 94.9 ± 1.4a 
SAGM 3.1 ± 0.2a 95.3 ± 1.6a 
SACH 2.4 ± 0.4b 94.1 ± 2.7a 
abMean values (±standard deviation) within the same column not sharing a common superscript 587 
differ significantly (P < 0.05). SA: microcapsules were prepared using alginate. SACM: 588 
microcapsules were produced using alginate and cow milk at a ratio of 1.5:1 (v/v). SAGM: 589 
microcapsules were produced using alginate and goat milk at a ratio of 1.5:1 (v/v). SACH: 590 
microcapsules were prepared using alginate and casein hydrolysate at a ratio of 1.5:1 (v/v). 591 
 592 
 593 
Table 2. Changes in the viability of free and encapsulated B. longum subsp. infantis CCUG 594 
52486 in cow milk at 4 oC for 28 days. 595 
Type of capsule Period of storage (days) 
0 7 14 21 28 
SA (log cfu g-1) 8.53 ± 0.09A a 8.05 ± 0.09A b 7.38 ± 0.09B c 6.84 ± 0.40B c 6.03 ± 0.04C c 
SACM (log cfu g-1) 8.57 ± 0.11A a 8.42 ± 0.05AB a 8.25 ± 0.07BC b 8.13 ± 0.11C b 7.07 ± 0.15D b 
SAGM (log cfu g-1) 8.63 ± 0.31A a 8.59 ± 0.17A a 8.54 ± 0.03A a 8.52 ± 0.06A a 7.61 ± 0.24B a 
SACH (log cfu g-1) 8.49 ± 0.03A a 7.63 ± 0.06B c 6.93 ± 0.18C d 6.38 ± 0.38C c 5.50 ± 0.05D d 
Free Cells (log cfu mL-1) 8.65 ± 0.12A a 7.13 ± 0.16B d 5.10 ± 0.07C e 4.83 ± 0.10C d 4.38 ± 0.29D e 
ABCDMeans in the same row without common letter differ significantly (p<0.05) for each type 596 
of microcapsules. abcdeMeans in the same column for each type of microcapsule without 597 
common letter differ significantly (p<0.05) for a particular day of storage. Data are expressed 598 
as mean ± standard deviation. For legend explanations see   599 
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